FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Sopsamorn Flavell

Research Profile

Chemicals & Drugs

Living Beings

Co-author Network

Publications

TOP 3
Francesco Giansanti; Luana Di Leandro; Ilias Koutris; Giuseppina Pitari; Maria Serena Fabbrini; Alessio Lombardi; David Flavell; Sopsamorn U Flavell; Stefano Gianni; Rodolfo Ippoliti
Engineering a switchable toxin: the potential use of PDZ domains in the expression, targeting and activation of modified saporin variants.
Alessio Lombardi; Sara Bursomanno; Teresa Lopardo; Roberta Traini; Marco Colombatti; Rodolfo Ippoliti; David Flavell; Sopsamorn U Flavell; Aldo Ceriotti; Maria Serena Fabbrini
Pichia pastoris as a host for secretion of toxic saporin chimeras.
David Flavell; Sarah L Warnes; Christine J Bryson; Sarah A Field; Armorel L Noss; Graham Packham; Sopsamorn U Flavell
The anti-CD20 antibody rituximab augments the immunospecific therapeutic effectiveness of an anti-CD19 immunotoxin directed against human B-cell lymphoma.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Sopsamorn Flavell (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2010: Francesco Giansanti; Luana Di Leandro; Ilias Koutris; Giuseppina Pitari; Maria Serena Fabbrini; Alessio Lombardi; David Flavell; Sopsamorn U Flavell; Stefano Gianni; Rodolfo Ippoliti
Engineering a switchable toxin: the potential use of PDZ domains in the expression, targeting and activation of modified saporin variants.
Protein engineering, design & selection : PEDS 2010;23(2):61-8.
2010: Alessio Lombardi; Sara Bursomanno; Teresa Lopardo; Roberta Traini; Marco Colombatti; Rodolfo Ippoliti; David Flavell; Sopsamorn U Flavell; Aldo Ceriotti; Maria Serena Fabbrini
Pichia pastoris as a host for secretion of toxic saporin chimeras.
FASEB journal : official publication of the Federation of American Societies for Experimental Biology 2010;24(1):253-65.
2006: David Flavell; Sarah L Warnes; Christine J Bryson; Sarah A Field; Armorel L Noss; Graham Packham; Sopsamorn U Flavell
The anti-CD20 antibody rituximab augments the immunospecific therapeutic effectiveness of an anti-CD19 immunotoxin directed against human B-cell lymphoma.
British journal of haematology 2006;134(2):157-70.
2005: Riccardo Vago; Catherine J Marsden; J Michael Lord; Rodolfo Ippoliti; David Flavell; Sopsamorn U Flavell; Aldo Ceriotti; Maura Fabbrini
Saporin and ricin A chain follow different intracellular routes to enter the cytosol of intoxicated cells.
The FEBS journal 2005;272(19):4983-95.
2003: David Flavell; Sopsamorn U Flavell; Richard Sullivan
European Clinical Trials Directive: responses made to MHRA consultation letter MLX 287.
Lancet 2003;362(9393):1415.
2001: David Flavell; D A Boehm; Armorel L Noss; Sarah L Warnes; Sopsamorn U Flavell
Therapy of human T-cell acute lymphoblastic leukaemia with a combination of anti-CD7 and anti-CD38-SAPORIN immunotoxins is significantly better than therapy with each individual immunotoxin.
British journal of cancer 2001;84(4):571-8.
2001: David Flavell; Sopsamorn U Flavell
Comparison of immunotoxins bearing a single saporin molecule with multiple toxin conjugates.
Methods in molecular biology (Clifton, N.J.) 2001;166():87-100.
2000: David Flavell; Sarah L Warnes; Armorel L Noss; Sopsamorn U Flavell
Anti-CD7 antibody and immunotoxin treatment of human CD7(+)T-cell leukaemia is significantly less effective in NOD/LtSz-scid mice than in CB.17 scid mice.
British journal of cancer 2000;83(12):1755-61.
1998: David Flavell; Sarah L Warnes; Armorel L Noss; Sopsamorn U Flavell
Host-mediated antibody-dependent cellular cytotoxicity contributes to the in vivo therapeutic efficacy of an anti-CD7-saporin immunotoxin in a severe combined immunodeficient mouse model of human T-cell acute lymphoblastic leukemia.
Cancer research 1998;58(24):5787-94.
1997: David Flavell; Armorel L Noss; Karen Pulford; N Ling; Sopsamorn U Flavell
Systemic therapy with 3BIT, a triple combination cocktail of anti-CD19, -CD22, and -CD38-saporin immunotoxins, is curative of human B-cell lymphoma in severe combined immunodeficient mice.
Cancer research 1997;57(21):4824-9.
1997: David Flavell; D A Boehm; Armorel L Noss; Sopsamorn U Flavell
Comparison of the potency and therapeutic efficacy of the anti-CD7 immunotoxin HB2-saporin constructed with one or two saporin moieties per immunotoxin molecule.
British journal of cancer 1997;75(7):1035-43.
1995: David Flavell; Sopsamorn U Flavell; D A Boehm; L Emery; Armorel L Noss; N R Ling; P R Richardson; D Hardie; DH Wright
Preclinical studies with the anti-CD19-saporin immunotoxin BU12-SAPORIN for the treatment of human-B-cell tumours.
British journal of cancer 1995;72(6):1373-9.
1995: David Flavell; D A Boehm; L Emery; Armorel L Noss; A Ramsay; Sopsamorn U Flavell
Therapy of human B-cell lymphoma bearing SCID mice is more effective with anti-CD19- and anti-CD38-saporin immunotoxins used in combination than with either immunotoxin used alone.
International journal of cancer. Journal international du cancer 1995;62(3):337-44.
1995: David Flavell; S Cooper; K Okayama; L Emery; Sopsamorn U Flavell
Comparison of the performance of anti-CD7 and anti-CD38 bispecific antibodies and immunotoxins for the delivery of saporin to a human T-cell acute lymphoblastic leukemia cell line.
Hematological oncology 1995;13(4):185-200.
1994: David Flavell; D A Boehm; K Okayama; J A Kohler; Sopsamorn U Flavell
Therapy of human T-cell acute lymphoblastic leukaemia in severe combined immunodeficient mice with two different anti-CD7-saporin immunotoxins containing hindered or non-hindered disulphide cross-linkers.
International journal of cancer. Journal international du cancer 1994;58(3):407-14.
1994: B J Morland; J Barley; D Boehm; Sopsamorn U Flavell; N Ghaleb; J A Kohler; K Okayama; B Wilkins; David Flavell
Effectiveness of HB2 (anti-CD7)--saporin immunotoxin in an in vivo model of human T-cell leukaemia developed in severe combined immunodeficient mice.
British journal of cancer 1994;69(2):279-85.
1994: B J Morland; D Boehm; Sopsamorn U Flavell; J A Kohler; David Flavell
Immunotoxin studies in a model of human T-cell acute lymphoblastic leukemia developed in severe combined immune-deficient mice.
Cell biophysics 1994;24-25():315-29.
1992: David Flavell; S Cooper; B Morland; R French; Sopsamorn U Flavell
Effectiveness of combinations of bispecific antibodies for delivering saporin to human acute T-cell lymphoblastic leukaemia cell lines via CD7 and CD38 as cellular target molecules.
British journal of cancer 1992;65(4):545-51.
1992: S H Lim; Trevor P Baglin; David Flavell; Sopsamorn U Flavell; J Z Wimperis; Robert E Marcus
High-dose mitoxantrone and etoposide conditioning in autologous bone marrow transplantation for relapsed Hodgkin's disease.
European journal of haematology 1992;48(2):110-4.
1991: David Flavell; S Cooper; B Morland; Sopsamorn U Flavell
Characteristics and performance of a bispecific F (ab'gamma)2 antibody for delivering saporin to a CD7+ human acute T-cell leukaemia cell line.
British journal of cancer 1991;64(2):274-80.
1991: Sopsamorn U Flavell; David Flavell
The anti-mitozantrone monoclonal antibody NO-1, protects acute leukaemia cell lines from the cytotoxic effects of mitozantrone.
British journal of haematology 1991;78(3):330-3.
1989: W P Stross; R A Warnke; David Flavell; Sopsamorn U Flavell; D Simmons; K C Gatter; D Y Mason
Molecule detected in formalin fixed tissue by antibodies MT1, DF-T1, and L60 (Leu-22) corresponds to CD43 antigen.
Journal of clinical pathology 1989;42(9):953-61.
1988: Sopsamorn U Flavell; David Flavell
Development of a sensitive monoclonal antibody-based enzyme-linked immunosorbent assay (ELISA) for mitozantrone.
Journal of immunological methods 1988;115(2):179-85.
1986: David Flavell; Sopsamorn U Flavell
Opisthorchis viverrini: pathogenesis of infection in immunodeprived hamsters.
Parasite immunology 1986;8(5):455-66.
1983: David Flavell; Sopsamorn U Flavell; G F Field
Opisthorchis viverrini: the relationship between egg production, worm size and intensity of infection in the hamster.
Transactions of the Royal Society of Tropical Medicine and Hygiene 1983;77(4):538-45.
1980: David Flavell; K Pattanapanyasat; Sopsamorn U Flavell
Opisthorchis viverrini: partial success in adoptively transferring immunity with spleen cells and serum in the hamster.
Journal of helminthology 1980;54(3):191-7.